Table 3 Crude MDS/AML rates by treatment category
Treatment category | % (cases/no. in category) (95% CI) |
|---|---|
2 years of follow up (n = 5790) | |
All patients | .29 (17/5790) (.17, .47) |
Surgery only | 0 (0/420) (0) |
Surgery/radiation | .25 (7/2764) (.10, .52) |
Surgery/chemotherapy | .16 (1/639) (.00, .87) |
Surgery/radiation/chemotherapy | .41 (9/1959) (.21, .87) |
Anthracycline regimen | .25 (5/1968) (.08, .59) |
Non-anthracycline regimen | .47 (3/633) (.10, 1.38) |
5 years of follow up (n = 4179) | |
All patients | .41 (17/4179) (.24, .65) |
Surgery only | 0 (0/222) (0) |
Surgery/radiation | .24 (5/2058) (.08, .57) |
Surgery/chemotherapy | .22 (1/461) (.01, 1.20) |
Surgery/radiation/chemotherapy | .42 (6/1440) (.15, .90) |
Anthracycline regimen | .15 (2/1368) (.02, .53) |
Non-anthracycline regimen | .56 (3/531) (.12, 1.64) |